Terns Pharmaceuticals, Inc. (TERN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Terns Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Terns Pharmaceuticals, Inc. (TERN) has returned 30.50% so far this year and 1,810.14% over the past 12 months.

Based on dividend-adjusted daily data since Feb 5, 2021, TERN's average daily return is +0.26%, while the average monthly return is +6.98%. At this rate, your investment would double in approximately 0.9 years.

Historically, 48% of months were positive and 52% were negative. The best month was Nov 2025 with a return of +240.3%, while the worst month was Feb 2022 at -47.1%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.

On a daily basis, TERN closed higher 48% of trading days. The best single day was Nov 3, 2025 with a return of +69.9%, while the worst single day was Mar 4, 2021 at -26.4%.

Terns Pharmaceuticals, Inc. has an annualized alpha of 72.88%, beta of 0.90, and R² of 0.02 versus S&P 500 Index. Calculated based on daily prices since February 08, 2021.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (96.24%) than losses (39.77%) — typical of diversified or defensive assets.
• R² of 0.02 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

TERN ranks 100 for risk / return — in the top 100% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Terns Pharmaceuticals, Inc. (TERN) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Terns Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Terns Pharmaceuticals, Inc. was 94.50%, occurring on May 11, 2022. Recovery took 884 trading sessions.

The current Terns Pharmaceuticals, Inc. drawdown is 0.85%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Terns Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Terns Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.